Zelber-Sagi S, Salomone F, Mlynarsky L
The door is the worst location
Key outcomes: Mean weight loss: 14.9% (vs 2.4% placebo) 86.4% of participants achieved 5% loss (vs 31.5% placebo) 50.5% achieved 15% loss (vs 4.9% placebo) SELECT (Lincoff et al., NEJM 2023) added the cardiovascular signature: in 17,604 non-diabetic adults with prior CV history, semaglutide 2.4 mg reduced MACE (CV death, MI, stroke) by 20% over 3 years
pairing medication with lifestyle
In vitro systems are useful for identifying key metabolic nodes and their threshold effects, but differences in amino acid concentrations in culture media, stimulation conditions, and criteria for polarization assessment may all affect the extrapolatability of the conclusions
Adenovirus 36 increases the risk of obesity in humans, characterized by increased inflammation and adiposity (255)